{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:28:55Z","timestamp":1791379735768,"version":"4.3.3"},"reference-count":26,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>The American medical landscape is currently defined by a profound paradox. While the ongoing opioid crisis, characterized by a rise in synthetic illicit opioids continues to ravage communities, our primary pharmacological defense for both opioid use disorder (OUD) and chronic pain management remains underutilized in the very training programs designed to produce \u201cexperts\u201d in the field. Pain medicine fellowship training frequently emphasizes the technical mastery of interventional procedures and non-opioid pharmacologic strategies. While these approaches are critically important, education in medication-assisted treatment (MAT), particularly the use of buprenorphine for OUD and complex chronic pain, often receives limited attention. The transition from the restrictive \u201cX-waiver\u201d era to the current regulatory environment was intended to expand and democratize access to buprenorphine treatment. However, legislative change alone cannot substitute for structured clinical education. Removing regulatory barriers does little to improve access if clinicians lack the knowledge, confidence, and training necessary to prescribe and manage these medications effectively. As the opioid crisis persists, it is critical that buprenorphine education be standardized as a core competency within pain medicine fellowship programs. Future pain specialists should be as comfortable initiating and managing buprenorphine therapy as they are performing advanced interventional procedures such as spinal cord stimulation. Strengthening training in this area will better equip pain physicians to address both chronic pain and opioid use disorder within an evolving and increasingly complex public health landscape.<\/jats:p>","DOI":"10.64719\/pb.18525","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:56:35Z","timestamp":1780995395000},"page":"109-116","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Exposure: Standardizing Buprenorphine Training in Pain Medicine Fellowship"],"prefix":"10.64719","volume":"56","author":[{"given":"Jamal","family":"Hasoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hasoon J, Nguyen A, Urits I, Robinson C, Viswanath O, Kaye AD. A need for further education on buprenorphine in pain medicine. Health Psychol Res. 2023;11:74958. doi: 10.52965\/001c.74958.","DOI":"10.52965\/001c.74958"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Dalal S, Chitneni A, Berger AA et al. Buprenorphine for chronic pain: a safer alternative to traditional opioids. Health Psychol Res. 2021;9(1):27241. doi: 10.52965\/001c.27241.","DOI":"10.52965\/001c.27241"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Pergolizzi JV, Jr, Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;12:3299\u20133317. doi: 10.2147\/JPR.S231948.","DOI":"10.2147\/JPR.S231948"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Poliwoda S, Noor N, Jenkins JS et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3):37517. doi: 10.52965\/001c.37517.","DOI":"10.52965\/001c.37517"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Levin JS, Landis RK, Sorbero M, Dick AW, Saloner B, Stein BD. Differences in buprenorphine treatment quality across physician provider specialties. Drug Alcohol Depend. 2022;237:109510. doi: 10.1016\/j.drugalcdep.2022.109510. Epub 2022 May 23.","DOI":"10.1016\/j.drugalcdep.2022.109510"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Yousufzai W, Credo R, Baronia R, Marambage K, Alag P. Navigating treatment transitions: enhancing outpatient recovery with morphine milligram equivalent (MME) dosing in methadone to bu-prenorphine transition-case reports. J Opioid Manag. 2025;21(5):461\u2013466. doi: 10.5055\/jom.0923.","DOI":"10.5055\/jom.0923"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Azar P, Nikoo M, Miles I. Methadone to buprenorphine\/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method. Am J Addict. 2018;27(8):601\u2013604. doi: 10.1111\/ajad.12809. Epub 2018 Nov 2.","DOI":"10.1111\/ajad.12809"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Hasoon J, Nguyen A, Viswanath O, Abd-Elsayed A. Challenges in transitioning from methadone to buprenorphine-naloxone for chronic pain management: two cases. Psychopharmacol Bull. 2025;55(3):60\u201365. doi: 10.64719\/pb.4536.","DOI":"10.64719\/pb.4536"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mendoza S, Rivera-Cabrero AS, Hansen H. Shifting blame: buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry. 2016;53(4):465\u201387. doi: 10.1177\/1363461516660884. Epub 2016 Aug 3.","DOI":"10.1177\/1363461516660884"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(Suppl 3):954\u2013963. doi: 10.1007\/s11606-020-06257-4. Epub 2020 Nov 3.","DOI":"10.1007\/s11606-020-06257-4"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Textor L, Ventricelli D, Aronowitz SV. \u2018Red Flags\u2019 and \u2018Red Tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States. Int J Drug Policy. 2022;105:103703. doi: 10.1016\/j.drugpo.2022.103703. Epub 2022 May 10.","DOI":"10.1016\/j.drugpo.2022.103703"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Rawal S, Welsh JW, Yarbrough CR et al. Community pharmacy-based buprenorphine programs and pharmacists\u2019 roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: a systematic review. J Am Pharm Assoc (2003). 2025;65(2):102319. doi: 10.1016\/j.japh.2024.102319. Epub 2024 Dec 27.","DOI":"10.1016\/j.japh.2024.102319"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hendy LE, Hill LG, Olguin A et al. Pharmacy barriers to receiving buprenorphine among patients undergoing telemedicine addiction treatment. JAMA Netw Open. 2025;8(8):e2527418. doi: 10.1001\/jamanetworkopen.2025.27418.","DOI":"10.1001\/jamanetworkopen.2025.27418"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Hasoon J, Chitneni A, Viswanath O, Urits I, Imani F, Varrassi G. Trends in outpatient buprenorphine prescribing for chronic pain: a retrospective analysis over 18 months. Psychopharmacol Bull. 2025;55(3):8\u201319. doi: 10.64719\/pb.4529.","DOI":"10.64719\/pb.4529"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Thompson MG, Kuriyama A, Yoshino T, Murphy MG, Jackson JL. Buprenorphine use in the United States, 2010\u20132019. Am J Med. 2024;137(3):280\u2013283. doi: 10.1016\/j.amjmed.2023.11.004. Epub 2023 Nov 19.","DOI":"10.1016\/j.amjmed.2023.11.004"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Larochelle MR, Jones CM, Zhang K. Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016\u20132021. Drug Alcohol Depend. 2023;248:109933. doi: 10.1016\/j.drugalcdep.2023.109933. Epub 2023 May 18.","DOI":"10.1016\/j.drugalcdep.2023.109933"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff (Millwood). 2020;39(6):984\u2013992. doi: 10.1377\/hlthaff.2019.01622.","DOI":"10.1377\/hlthaff.2019.01622"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Harris MTH, Weinstein ZM, Walley AY. Medications for opioid use disorder, opioid withdrawal, and opioid overdose: a review. JAMA. 2026 doi: 10.1001\/jama.2025.26348. Epub ahead of print.","DOI":"10.1001\/jama.2025.26348"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"McCollum CG, Eaton E, Creger T, Lee A, Gagnon K, Li L. Physicians\u2019 experiences with buprenorphine: a qualitative study of motivations for becoming X waivered and barriers to and facilitators of prescribing the medication for opioid use disorder. Drug Alcohol Depend. 2023;244:109777. doi: 10.1016\/j.drugalcdep.2023.109777. Epub 2023 Jan 16.","DOI":"10.1016\/j.drugalcdep.2023.109777"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Egan JE, Casadonte P, Gartenmann T et al. The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand\/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936\u201341. doi: 10.1007\/s11606-010-1377-y. Epub 2010 May 11.","DOI":"10.1007\/s11606-010-1377-y"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Goel A, Azargive S, Weissman JS et al. Perioperative pain and addiction interdisciplinary network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth. 2019;123(2):e333-e342. doi: 10.1016\/j.bja.2019.03.044. Epub 2019 May 29.","DOI":"10.1016\/j.bja.2019.03.044"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Vu PD, Bansal V, Chitneni A et al. Buprenorphine for chronic pain management: a narrative review. Curr Pain Headache Rep. 2023;27(12):811\u2013820. doi: 10.1007\/s11916-023-01185-4. Epub 2023 Oct 28.","DOI":"10.1007\/s11916-023-01185-4"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Buresh M, Ratner J, Zgierska A, Gordin V, Alvanzo A. Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations. J Gen Intern Med. 2020;35(12):3635\u20133643. doi: 10.1007\/s11606-020-06115-3. Epub 2020 Aug 21.","DOI":"10.1007\/s11606-020-06115-3"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Goel A, Azargive S, Weissman JS et al. Perioperative pain and addiction interdisciplinary network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth. 2019;123(2):e333\u2013e342. doi: 10.1016\/j.bja.2019.03.044. Epub 2019 May 29.","DOI":"10.1016\/j.bja.2019.03.044"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Spreen LA, Dittmar EN, Quirk KC, Smith MA. Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review. Pharmacotherapy. 2022;42(5):411\u2013427. doi: 10.1002\/phar.2676. Epub 2022 Mar 25.","DOI":"10.1002\/phar.2676"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Hasoon J, Nguyen A, Robinson CL. Managing acute surgical pain in patients on buprenorphine: a case-based learning module. Orthop Rev (Pavia). 2026;18:158284. doi: 10.52965\/001c.158284.","DOI":"10.52965\/001c.158284"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:37:10Z","timestamp":1791315430000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/beyond-exposure-standardizing-buprenorphine-training-in-pain-medicine-fellowship\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.18525","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}